Tsumura & Co.
Supplementary Financial Materials
Supplementary materials for the consolidated results for the second quarter (interim) of fiscal 2026. Consolidated net sales were 89,897 million yen, an increase of 14,?% year-over-year (there are unclear parts in the source regarding the year-over-year figure). The breakdown by domestic and China businesses and sales trends for 129 prescription Kampo formulations are disclosed. Notes on the impact of consolidating the Shanghai subsidiary and PPA-related considerations are included.
Key Figures
- Net Sales: 89,897 million yen (YoY increase)
- Operating Income: 17,119 million yen (YoY increase)
- Net Income Attributable to Owners of Parent: 12,477 million yen (YoY increase)
AI要約
Performance Overview
Tsumura & Co. released supplementary materials for its consolidated results for the second quarter (interim) of fiscal 2026. Net sales were 89,897 million yen, showing a substantial increase compared with the same period last year; operating income was 17,119 million yen and net income attributable to owners of parent was 12,477 million yen, both increased. Contributions from the domestic business and the China business are shown; the China business exhibited phases of slowdown and re-expansion, while overall margin improvement is notable. The impact of consolidating Yomeishu Seizo is noted.
Impact on Shareholders and Notes
Due attention is required when comparing financial statements due to the consolidation of Yomeishu Seizo. Trends in the sales composition ratio should be reviewed, particularly changes in the ratios of the domestic and China businesses. Note that amounts finalized after PPA may affect full-year forecasts. Cash and cash equivalents at the end of the period increased, which can be interpreted as indicating sound liquidity.
Tsumura & Co.
Company overview · Stock price · Financial data · All IR
